Animal Gastroesophageal Reflux Disease Market – By Product, By Animal Type - Global Forecast 2025 - 2034

Animal Gastroesophageal Reflux Disease Market Size

The global animal gastroesophageal reflux disease market was estimated at USD 3.1 billion in 2024. The market is expected to grow from USD 3.3 billion in 2025 to USD 6.3 billion in 2034, at a CAGR of 7.5%. The increasing prevalence of gastroesophageal reflux disease (GERD) in both companion and livestock animals is a key driver of market growth. As an example, an article in the Journal of Small Animal Practice in January 2023 reported that 50% of dogs were demonstrating signs of gastroesophageal reflux, illustrating the degree to which the problem is prevalent.
 

Moreover, as in humans, bacterial infections and some other diseases of the gastrointestinal tract may cause gastroesophageal reflux disease in animals, which helps expand the market even further. For instance, some pets suffering from bacterial gastrointestinal infections may experience acid reflux because of gastrointestinal dysfunction. Studies have shown the increasing cases of Helicobacter pylori infections, which are common in pets with chronic vomiting or gastritis, are causative factors in developing gastroesophageal reflux disease in companion animals, which further raises the demand for diagnostic tests such as helicobacter pylori testing and therapeutics.
 

Moreover, as the veterinary care industry continues to evolve, the increasing number of companion animals, especially dogs and cats, is stimulating market growth. For example, Statista mentioned 33 million dog population in India which would rise to 51 million in 2028. Additionally, the growing pet ownership and increased focus on  pet care is expanding the market growth. According to Health for Animals, more than half of the global population is estimated to have at least one pet. Additionally, the increasing ownership has resulted in increasing companion animal spending, that drives the growth of the market.
 

In addition, older patients have a higher susceptibility because of the changes in their digestive system, which include the attempt to relax the esophageal sphincter, decreased motility, and a slower rate of digestion. The increasing rate of obesity in such patients as well as the slower gastric emptying will further aid in the stimulation of Growth.
 

Moreover, the treatment and diagnosis of GERD in animals is being more actively undertaken due to the increasing attention given to sophisticated diagnostic tests and treatment drugs in veterinary medicine. The development of gastroesophageal reflux disease (GERD) is now more manageable due to advances in veterinary medicine like endoscopes, ultrasound imaging devices, and specialized blood tests which enable early and accurate diagnosis.
 

Animal gastroesophageal reflux disease is a disorder characterized by stomach acid or bile irritates the esophagus and the inflammation of the lining of the esophagus that leads to tissue destruction. This disease is common in dogs and cats and can result in symptoms ranging from vomiting to abdominal pain. GERD is mostly due to lower esophageal sphincter relaxation and other parts of the body in the digestive tract. When the condition occurs without therapeutic measures, it results in persistent inflammation of the esophagus and other serious conditions.
 

Animal Gastroesophageal Reflux Disease Market Trends

• The market is stimulated by technological advancements, increased health awareness, and rising expenditure for pets and livestock. The growing focus on preventive healthcare also contributes to market growth. For instance, leading companies in the sector are launching a wide range of treatments, therapeutics, and diagnostic solutions that help improve gastroesophageal reflux disease management in both companion animals and livestock.
   
• Innovations in diagnostics and proprietary treatment modalities are accelerating the market for animal GERD solutions. More sophisticated diagnostic instruments, such as endoscopes and other non-invasive modalities, now allow for safe and effective identification of gastroesophageal reflux disease and its complications in animals by veterinary practitioners.
   
• These advances allow for further enhancement in the detection and management of GERD, thus helping to improve animal health. In addition, other formulations of therapeutic diets with more controlled ingredients, hydrolyzed proteins and foods high in prebiotics, alongside increased focus on research dedicated to the development of specific treatment protocols are further augmenting the growth.
   
• A shift towards pet humanization contributes to market growth by increasing the demand for pet health solutions, especially for gastrointestinal health. Pet owners are more focused on investing in high-quality health products and therapies for animals, considering them as important members of the family.
   
• This has resulted in growing specialized treatments for conditions such as GERD, where just pet food and medications are not sufficient. As a result, the market for gastroesophageal reflux disease special treatments and health management solutions is expanding.
   
• The increasing trend of preventive healthcare for pets is advancing the demand for solutions related to gastroesophageal reflux disease. New health products, their development is aided by a growing range of nutritional supplements, treatments, and dietary solutions like vitamin and probiotic enriched foods which reduce the chances of GERD episodes and aid in maintaining a healthy digestive tract.
   
• Moreover, natural and organic pet products and supplements are in higher demand as more pet owners prefer organic and chemical-free options, which is also helpful for animal gastroesophageal reflux disease. These trends are positively impacting natural GERD treatment options.
   
• Lastly, veterinary telemedicine and remote consultations are becoming increasingly popular which positively effects this market. Telemedicine assists in making GERD treatment more accessible, allowing for at-home management of the condition, to the convenience of pet owners. This increased accessibility to easily prescribed and remotely monitored products and services has resulted in a greater demand from pet owners in remote areas.
   

Trump Administration Tariffs

• The Trump administration’s import tariffs on veterinary diagnostic equipment and electronic components from China may inflate the costs associated with raw materials as well as gastro-monitoring devices. These tariffs may also cause logistic supply chain complications because a large number of animal GERD solution manufacturers depend on Chinese suppliers for low-cost endoscopy instruments, pH monitoring units, and veterinary diagnostic consumables.
   
• With these tariffs in place, firms participating in the animal gastroesophageal reflux disease market might strategize on a lower dependency on Chinese production capabilities and reevaluate their supply chain configurations, which would require the alterations of production processes. This can result in favorable operational shifts towards supply countries like India, Vietnam, and Eastern Europe.
   
• Furthermore, other short-term factors like materiel validators not being available when needed, diversifying vendors causing heightened operational expenditures, and possible cooling of after-sales service for diagnostic, monitoring, and therapeutic devices add to the complications.
   

Animal Gastroesophageal Reflux Disease Market Analysis

In 2021, the global market was valued at USD 2.6 billion. The following year, it saw a slight increase to USD 2.7 billion, and by 2023, the market further climbed to USD 2.9 billion.
 

Based on product, the global market is divided into diagnostics and treatment. The treatment segment dominated the market in 2024 with USD 1.7 billion.
 

• Gastrointestinal therapeutics such as antacids, H2 antagonists, and proton pump inhibitors show consistent effectiveness in reducing stomach acid in animals, which is important for controlling GERD symptoms. The positive outcome in treating human GERD further supports the treatment application in veterinary care. Safety and less side effects are generally well understood, and they have been used in veterinary medicine for years.
   
• These medications are widely available in both human and veterinary formulations. For example, drugs such as famotidine (H2 antagonist) and omeprazole (PPI) are sold over the counter, which makes them easily accessible to veterinarians and pet owners. Large-scale production of treatment solutions and well-established supply chains makes them readily accessible in the veterinary market.
   
• Additionally, the cost-effectiveness of these drugs makes them advantageous for widespread use. Furthermore, with years of experience in veterinary practice, there is a stronger understanding of the proper dosages, treatment protocols, and potential side effects, which increases confidence in using them to manage GERD. As stated by the NIH, the treatment option that has been most often utilized for gastroesophageal reflux disease is medical therapy, where the management of GERD is most effectively done by proton pump inhibitors.

Based on animal type, the global animal gastroesophageal reflux disease market is categorized into companion animals and livestock animals. In 2024, the companion animals segment accounted for the largest share of 71.7% in global market.
 

• Obesity in pets is on the rise, leading to nutritional deficits in many companion animals. This is especially true for commercially used pet foods that are high in fat, additives, and preservatives. Such dietary issues often lead to the development of acid reflux, augmenting the need in the market for GERD treatment options. In addition to irregular feeding schedules and portion sizes, excessive use of treats also increases the need for therapeutic and diagnostic interventions.
   
• Pulsating dog breeds such as pugs, bulldogs, and boxers constitute a special group of dogs that suffer from heightened susceptibility to GERD because of the peculiar facial chronic stress model they are obese esophageal body shape radiating out the valve dysplasia increases.
   
• The aging pet population also contributes significantly to GERD prevalence. Senior animals undergo rapid health declines, further aggravating GERD problems due to severe gastrointestinal deterioration, dreadfully increased acid reflux, and other drastically declining health conditions such as kidney disease which worsen their stomach health.
   
• In addition, other primary medical problems such as inflammatory bowel disease also contribute to an increased risk factor for GERD along with some known medications that reduce the efficiency of the lower esophageal sphincter. This creates greater need for reliable GERD tests and efficient treatment methods.

In 2024, the U.S. held a significant position in the North America animal gastroesophageal reflux disease market, valued at USD 1.2 billion.
 

• The increasing number of pet ownership in the U.S. is increasing rapidly, thus further stimulating the growth of the market. According to the American Veterinary Medical Association, an average overall amount of spending on pets by pet-owning households, excluding adoption or purchase costs, is around USD 1,515 per year. This increases the supply of veterinary services demanded by veterinary professionals and pet owners even more.
   
• Not only humans, but animals too, with a focus on preventive healthcare, is an evolving trend in the U.S., which supports market expansion. There is growing awareness amongst pet owners and livestock breeders regarding the importance of mitigation in gastrointestinal health and the overall health of animals.
   
• Additionally, government initiatives are focusing on avoiding diseases and improving animal welfare by investing in research and development and AI-driven methods for good gut health.
   

Germany dominates the European animal gastroesophageal reflux disease market, showcasing strong growth potential.
 

• The increasing pet care in both companion and livestock animals, along with government initiatives for disease prevention and good animal health, is stimulating the market growth. According to the International Trade Administration, there are 34.3 million pets in Germany and 45% of households have pets as of 2023.
   
• In addition, the increasing age of pets leads to chronic conditions, with GERD being one of them in older animals. Moreover, the contribution of obesity and other dietary challenges is critical to the demand of GERD solutions which fosters the growth of the market.
   
• BMEL has specialized programs that are aimed at improving animal health through the prevention of diseases and bettered intestinal health that drives the growth of animal gastroesophageal reflux disease treatment.
   
• The market is further propelled by the increasing supply of both natural and synthetic products. There is a continuous investment in the development of innovations products aimed at proper care and nutrition of the livestock, thus supporting the expansion of the market in Germany.
   

China animal gastroesophageal reflux disease market is estimated to grow with a significant CAGR, making it to be the fastest growing country in the Asia Pacific market.
 

• China holds the highest market share in the region, driven by the rising prevalence of diseases in animals, growing pet ownership, and increasing demand for natural preventive care.
   
• As China's urbanization continues, there has been a noticeable rise in pet ownership, particularly in urban areas. Owners are becoming increasingly concerned with maintaining the health of their pets—this now extends to ensuring proper digestion. The trend of pet humanization fuels the need for drugs for treating gastroesophageal reflux disease (GERD).
   
• China is focusing its resources more on the research and development of innovative solutions to problems in veterinary medicine. As noted by NIH, China leads in filing patents on probiotics and enzymes for livestock, indicating a commitment to pioneering gut health technologies. In addition, increased educational campaigns concerning the health of animals, coupled with government programs aimed at improving the welfare of animals, is creating demand for products that ensure proper gastrointestinal functioning in pets.
   
• There is a greater effort by companies to develop new and effective products through partnerships and collaborations. One example is the collaborative study on improving gastrointestinal health in animals conducted by China Agricultural University and Zhejiang University.
   
• In November 2023, Evonik China partnered with Shandong Vland Biotech to create Evonik Vland Biotech, a joint venture focusing on developing probiotics to improve intestinal health in animals.
   
• Such initiatives are expected to significantly contribute to the growth of the market by fostering the development of targeted solutions.
   

Brazil leads the Latin American animal gastroesophageal reflux disease market, with remarkable growth during the analysis period.
 

• The rising incidence of infectious diseases, along with increasing environmental and dietary stress in animals, is driving the growth of the gastroesophageal reflux disease market.
   
• The increasing concern for the effect of gastrointestinal disorders on the productivity of farm animals is changing the attitudes of veterinarians and farmers towards the proper management of these diseases, thus aiding in the growing market.
   
• Government policies targeted at improving veterinary services and general animal welfare in Brazil are positively impacting the growth of the gastroesophageal reflux disease market.
   
•  Additionally, the country's expanding veterinary healthcare sector, particularly in gastroenterology, is gaining momentum as awareness of animal GERD increases and more effective treatment options become available.
   
• In addition, veterinary collaborations with international pharmaceutical companies for the introduction of new therapeutic solutions, such as proton pump inhibitors, H2 blockers, and other medications that can help manage GERD in companion animals and livestock, further escalates the market growth.
   
• For instance, Royal DSM acquired Prodap, which is a Brazilian animal nutrition and technology company, to improve farming solutions and sustainability in animal farming. The acquisition provides customized nutritional solutions and insights for improved animal health that spur the market growth.
   

Saudi Arabia animal gastroesophageal reflux disease market to experience substantial growth in the Middle East and Africa market in 2024.
 

• The increasing focus on the aspects of animal health care and the welfare of livestock and companion animals is becoming a market driver. In Saudi Arabia, gastroesophageal reflux disease (GERD) is becoming an emerging concern for many pet owners, veterinarians, and livestock farmers due to harsh weather conditions, substandard feeding practices, and industrialized farming.
   
• The government's active interest in Animal health and veterinary service infrastructure development through its Vision 2030 program, which focuses on improving animal health care systems, enhances animal welfare and safety in the country, which creates a positive shift in the demand for animal health products and services.
   
• Furthermore, volunteers and metropolitan young adults attending more pet has resulted in greater cognizance of companion animal gastro-intestinal disorders which actively sustains the need for efficient interventions.
   

Animal Gastroesophageal Reflux Disease Market Share

Top 6 players such as AstraZeneca, Boehringer Ingelheim, Hill's Pet Nutrition, Pfizer, Virbac, and Zoetis account for approximately 50-60% of the market share. These players focus on various strategies such as business expansion, mergers and acquisitions, collaboration, and novel product launches to consolidate their market presence. For example, in 2023, Virbac launched veterinary HPM used as a digestive support for healthy diet intake.
 

Key players are engaging in strategic initiatives such as collaboration, product launches, and partnerships to strengthen their product portfolio. For instance, AstraZeneca and Pfizer have an agreement over the drug named Nexium that is used as an OTC drug in animal gastroesophageal reflux disease. These companies are actively adopting multi-pronged approaches to address the rising demand for animal gastroesophageal reflux disease solutions. The market is highly consolidated with few players operating in the market. Hence, leading players are constantly adopting key strategies for the growth of the market.
 

Animal Gastroesophageal Reflux Disease Market Companies

Prominent players operating in the market are as mentioned below:

• Boehringer Ingelheim
• Daiichi Sankyo
• Elanco Animal Health
• Hill's Pet Nutrition
• IDEXX Laboratories
• Kerry Group
• Merck
• Vetcare
• Vetoquinol
• Vibrac
• Zoetis
   

To maintain a competitive edge, key players are focusing on research and development, forming strategic partnerships, and pursuing collaborations to introduce new treatments for animal gastroesophageal reflux disease (GERD).
 

• Vetbiolix’s investigational drug, VBX-3000, is a potential first-in-class, next-generation prokinetic for companion animals. Designed to improve efficacy for canine gastroparesis and feline chronic constipation (coprostasis), VBX-3000 utilizes a novel mechanism as a selective 5-HT4 receptor agonist, aiming to restore coordinated GI motility and offer effective treatment for GERD in animals.
   
• RaQualia’s RQ-00000010, a novel 5-HT4 receptor agonist, is targeting gut motility disorders in dogs and cats. Currently in preclinical development, it shows promise as the first prokinetic therapy for canine GERD and related motility disorders, offering a breakthrough solution in a market with limited treatment options.
   
• These novel treatments, targeting GI motility disorders in dogs and cats, address the critical need for effective, safe solutions for canine GERD and related conditions, paving the way for more targeted and efficient treatments in the veterinary field. Therefore, these advancements are driving competition, raising awareness, and accelerating growth across the market.
   

Animal Gastroesophageal Reflux Disease Market Industry News

• In May 2024, Esaote North America launched MyLab FOX, a veterinary ultrasound system. The system features enhanced diagnostic precision, and a customizable design, offering a wide range of clinical applications. Its AI-powered tools, such as Easy Mode and XStrain technology, improve workflow efficiency and diagnostic accuracy. The MyLab FOX integrates into a digital ecosystem, ensuring connectivity and data management support for veterinarians.
   
• In April 2024, Royal Canin U.S. announced an expansion of its veterinary gastrointestinal (GI) portfolio with five new diets for cats and dogs. These diets address common gastrointestinal issues that prompt veterinary visits, and the new formulas aim to support digestive health in pets and enhance long-term digestive health.
   
• In January 2024, Innovative Solutions launched Humisyn, a product line designed to improve gut health in poultry and reduce the effects of necrotic enteritis, causing significant loss in the global poultry industry. The product is available in two forms: HumiSyn IFC4, a dry feed additive, and HumiSyn WSC4, a liquid supplement for drinking water. This helped the company expand its product offerings.
   

The animal gastroesophageal reflux disease market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Diagnostics
  • Test Type
    • Laboratory tests
    • Veterinary imaging
    • Other diagnostic tests
  • End use
    • Veterinary hospital and clinics
    • Veterinary diagnostic centers
    • Other end use
• Treatment     
  • Drug class
    • Antacids
    • H2 receptor blockers
    • Proton pump inhibitors (PPIs)
    • Pro-kinetic agents
    • Other drug classes
  • Route of administration
    • Oral
    • Injectables

Market, By Animal Type

• Companion animals 
• Livestock animals     

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE